ACTION: Notice; reopening of comment period.

SUMMARY: The Food and Drug Administration (FDA) is reopening until November 6, 2009, the comment period for the notice of public meeting and request for comments that appeared in the **Federal Register** of June 3, 2009 (74 FR 26712). In the notice of public meeting and request for comments, FDA's Transparency Task Force requested comments on ways in which FDA can make useful and understandable information about FDA activities and decision making more readily available to the public. The agency is taking this action because the agency is planning a second public meeting this fall and is reopening the comment period to allow interested persons additional time to submit comments.

DATES: Submit written or electronic comments by November 6, 2009.

ADDRESSES: Submit written comments to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.regulations.gov*. All such comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Afia Asamoah, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, rm. 2208, Silver Spring, MD 20993, 301–796–4625, FAX: 301–847–3531, e-mail: *Afia.Asamoah@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 3, 2009 (74 FR 26712), FDA published a notice of public meeting and request for comments on ways in which FDA can make useful and understandable information about FDA activities and decisionmaking more readily available to the public, in a manner compatible with the agency's goal of protecting confidential information, as appropriate. Interested persons were given until August 7, 2009, to submit comments. The agency is planning to hold a second meeting in the fall of 2009 about these issues and is reopening the comment period until November 6, 2009. FDA has also established an online blog at *http://fdatransparencyblog.fda.gov* in which interested persons may provide feedback on specific topics. The blog is expected to run through November 2009.

Interested persons may submit written or electronic comments to the Division of Dockets Management (see **ADDRESSES**). Submit a single copy of electronic comments to *http://www.reguations.gov* or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Dated: August 12, 2009.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E9–19778 Filed 8–17–09; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, National Center for Public Health Informatics (BSC, NCPHI)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

Time and Date: 8:30 a.m.–5 p.m., September 2, 2009.

Place: Hyatt Regency, 265 Peachtree Street NE., Atlanta, Georgia, 30303 *Tel:* (404) 577–1234, *Fax:* (404) 588–4137.

Maps & Directions

This meeting will also be teleconferenced: Toll Free Number: (866) 713–5586, Participant's pass code 4624038.

Status: Open to the public, limited only by the space available.

Purpose: The committee shall advise the Secretary, HHS, and the Director, CDC, concerning strategies and goals for the programs and research within the national centers; shall conduct peer-review of scientific programs; and monitor the overall strategic direction and focus of the national centers. The board, after conducting its periodic reviews, shall submit a written description of the results of the review and its recommendations to the Director, CDC. The board shall perform second-level peer review of applications for grants-in-aid for research and research training activities, cooperative agreements, and research contract proposals relating to the broad areas within the national center.

Matters to be Discussed: The board will discuss BSC, NCPHI-related matters, including an update on NCPHI Programs and other BSC-related activities.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Dr. Scott McNabb, National Center for Public Health Informatics, CDC, 1600 Clifton Road, NE., Mailstop E–78, Atlanta, Georgia 30333, Telephone (404) 498–6427, Fax (404) 498–6235.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substance and Disease Registry.

Dated: August 10, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–19754 Filed 8–17–09; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of General Medical Sciences; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory General Medical Sciences Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory General Medical Sciences Council.

Date: September 10–11, 2009.

Closed: September 10, 2009, 8:30 a.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Natcher Building, Conference Rooms E1 & E2, 45 Center Drive, Bethesda, MD 20892.

Open: September 11, 2009, 8:30 a.m. to adjournment.

Agenda: For the discussion of program policies and issues, opening remarks, report of the Director, NIGMS, and other business of the Council.

Place: National Institutes of Health, Natcher Building, Conference Rooms E1 & E2, 45 Center Drive, Bethesda, MD 20892.

Contact Person: Ann A. Hagan, PhD, Associate Director for Extramural Activities, NIGMS, NIH, DHHS, 45 Center Drive, Room 2AN24H, MSC6200, Bethesda, MD 20892–6200. (301) 594–4499. *hagana@nigms.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *http://www.nigms.nih.gov/about/advisory_council.html,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: August 10, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–19663 Filed 8–17–09; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2009–N–0376]

Office of the Commissioner Reorganization; Statement of Organizations, Functions, and Delegations of Authority

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has reorganized the Office of the Commissioner (OC). This reorganization includes the organizations and their substructure components as listed in this document. This reorganization includes the re-alignment of four Deputy-level offices within the Office of the Commissioner: the Office of the Chief Scientist; the Office of Administration (formerly titled the Office of Operations); the Office of Foods; and the Office of Policy, Planning and Budget (formerly titled the Office of Policy, Planning and Preparedness).

FOR FURTHER INFORMATION CONTACT: Vanessa Starks, Office of Management Programs (HFA–400), Food and Drug Administration, 5600 Fishers Lane, rm. 6B–42, Rockville, MD 20857, 301–827–1463.

Office of the Chief Scientist: The organizational change will allow the agency to better focus the science and research activities under the Chief Scientist. Re-alignments under the Office of the Chief Scientist will include the Office of Counter-Terrorism and Emerging Threats, Office of Critical Path Programs, Office of Scientific Integrity, and the Office of Science and Innovation.

Office of Administration: The Office of Operations will be re-titled the Office of Administration. The Office of Administration will be restructured to strengthen agency wide management programs, budget and shared services operations, as well as the Office of the Commissioner's executive operations. Realignments of the Office of Acquisitions and Grants Services, the Office of Executive Operations, the Office of Information Management, the Office of Management, the Office of Equal Employment Opportunity and Diversity Management, and the establishment of the Office of Financial Operations.

Office of Foods: The Office of Foods will be realigned from the Office of Operations and will report directly to the Commissioner.

Office of Policy, Planning and Budget: The Office of Policy, Planning and Preparedness will be retitled the Office of Policy, Planning and Budget. The realignments from the Office of Policy, Office of Planning, and the Office of Budget Formulation (formerly titled the Office of Budget Formulation and Presentation, Office of Operations).

[Part D, Chapter D–B, (Food and Drug Administration), the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (35 FR 3685, February 25, 1970, and 60 FR 56605, November 9, 1995, 64 FR 36361, July 6, 1999, 72 FR 50112, August 30, 2007) is amended to reflect the restructuring of the Office of the Commissioner (OC), Food and Drug Administration (FDA) as follows].

I. Under Part D, Food and Drug Administration, delete the Office of Commissioner in its entirety and replace with the following:

DA.10 ORGANIZATION. The Food and Drug Administration (FDA) is headed by the Commissioner, Food and Drug, and includes the following organizational units:

Office of the Commissioner
Office of the Chief Counsel
Office of the Chief of Staff
Office of Legislation
Office of Policy, Planning and Budget
Office of Counselor to the Commissioner
Office of Women's Health
Office of Special Medical Programs
Office of External Affairs
Office of Foods
Office of the Chief Scientist
Office of International Programs
Office of Administration
Office of Equal Employment Opportunity and Diversity Management
Center for Tobacco Products

DA.20 FUNCTIONS.

Office of the Commissioner: The Office of the Commissioner (OC) includes the Commissioner and Deputy Commissioner who are responsible for the efficient and effective implementation of the FDA mission.

Office of the Chief Counsel: The Office of the Chief Counsel (OCC) is also known as the Food and Drug Division, Office of the General Counsel, Department of Health and Human Services. While administratively within the Office of the Commissioner, the Chief Counsel is part of the Office of the General Counsel of the Department of Health and Human Services.

1. Is subject to the professional supervision and control of the General Counsel, Department of Health and Human Services (DHHS), and represents FDA in court proceedings and administrative hearings with respect to programs administered by FDA.

2. Provides legal advice and policy guidance for programs administered by FDA.

3. Acts as liaison to the Department of Justice and other Federal agencies for programs administered by FDA.

4. Drafts or reviews all proposed and final regulations and **Federal Register** notices prepared by FDA.

5. Performs legal research and gives legal opinions on regulatory issues, actions, and petitions submitted to FDA.